ImmunoCellular Therapeutics to Present at BIO CEO & Investor Conference on February 11th
February 4, 2013
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 15th Annual BIO CEO & Investor Conference on Monday, February 11, 2013 at 10:00 am ET at the Waldorf Astoria Hotel in New York City.

ImmunoCellular Therapeutics’ Investigational New Drug (IND) Application for ICT-140 Allowed by the FDA
January 29, 2013
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. ImmunoCellular filed the IND application with the FDA in the fourth quarter of 2012, as planned.

ImmunoCellular Therapeutics Provides Update on Corporate Milestones
January 7, 2013
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today provided an update on current and anticipated corporate milestones.

ImmunoCellular Therapeutics Appoints Gary S. Titus to its Board of Directors
January 2, 2013
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced the appointment of Gary S. Titus to its board of directors. Mr. Titus is currently the Senior Vice President and Chief Financial Officer of SciClone Pharmaceuticals, Inc. and has more than 20 years of business experience in the healthcare and biopharmaceutical industries. Mr. Titus has extensive experience in working with public corporations in a variety of areas, including financial planning and analysis, SEC reporting, investor relations, business development, and corporate strategy.

ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer
December 3, 2012
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today the appointment of Andrew Gengos as President and Chief Executive Officer and member of the Board of Directors. With more than 20 years in the life science industry, Mr. Gengos’ experience includes executive leadership positions in both large and emerging companies, with broad expertise in corporate strategy, business development and transactions, including mergers and acquisitions, financing, operations, commercial planning and healthcare policy.

ImmunoCellular Therapeutics Reports Third Quarter 2012 Financial Results
November 12, 2012
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced third quarter results for the period ended September 30, 2012.

ImmunoCellular Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th
November 5, 2012
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 11:00 am ET at the Pierre Hotel in New York City.

ImmunoCellular Therapeutics Provides an Update on Recent 2012 Achievements and Anticipated Milestones
November 1, 2012
Los Angeles, CA – ImmunoCellular Therapeutics Provides an Update on Recent 2012 Achievements and Anticipated Milestones. Commented John S. Yu, MD, Interim Chief Executive Officer: “We are pleased with our progress in the third quarter of 2012 and year to date. Our fundamentals are strong. This month, we completed a significant underwritten public financing, which provided approximately $19.3 million of cash, net of commissions and expenses, achieving our goal of capitalizing the company with sufficient cash runway to enable us to achieve our near-term objectives.

ImmunoCellular Therapeutics, Ltd. Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants
October 18, 2012
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 10,000,000 shares of its Common Stock, at a price to the public of $2.10 per share, and warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock. The net offering proceeds to ImmunoCellular from this offering are expected to be approximately $19.3 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding the exercise of any warrants and any exercise of the underwriters’ over-allotment option.

ImmunoCellular Therapeutics, Ltd. Announces Proposed Public Offering of Common Stock and Warrants
October 17, 2012
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) today announced that it intends to offer shares of its common stock and warrants in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering.

ImmunoCellular Therapeutics to Present at 3rd Annual Cancer Immunotherapy Conference and 2012 BIO Investor Forum
October 2, 2012
Los Angeles, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Peter Ho, PhD, Director of Business Development, will present a company overview at 2:00 pm ET and participate in a panel discussion on advances in immunotherapy for glioma at 2:45 pm ET at the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference on Thursday, October 4, 2012, at the New York Academy of Medicine.

ImmunoCellular Therapeutics Completes Enrollment of Phase II Trial of ICT-107 in Glioblastoma
September 5, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma. A total of 278 patients at 25 participating sites have been enrolled in this trial, which was initiated in January 2011.

ImmunoCellular Therapeutics to Present at Two September 2012 Investor Conferences
August 27, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the BioCentury and Thomson Reuters Newsmakers in the Biotech Industry Conference on September 7, 2012 at 11:30 am ET at the Millennium Broadway Hotel in New York City, and at the Rodman & Renshaw Annual Global Investment Conference on September 10, 2012 at 4:30 pm ET at the Waldorf-Astoria Hotel in New York City.

Press Archives